Press releases

Oxford BioMedica: Notice of Interim Results

Results date: 29 August 2013

Oxford, UK – 23 July 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, will be announcing its interim results for the six months ended 30 June 2013 on Thursday, 29 August 2013.

An analyst briefing will be held at 09:30am GMT on Thursday, 29 August 2013 at the offices of M:Communications, 11th Floor, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.  An audio replay will be made available shortly after the presentation on the Company's website: www.oxfordbiomedica.co.uk.

-Ends-

Notes to editors

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications – Media Enquiries

Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton

Tel: +44 (0)20 3709 5700

 

Jefferies (Corporate Broker) 

Gil Bar-Nahum/Simon Hardy/Lee Morton/Max Jones/Nicholas Moore

Tel: +44 (0)20 7029 8000